Paul Tudor Jones's CTMX Position Overview
Paul Tudor Jones (via Tudor Investment Corp Et Al) currently holds 1.38 M shares of CytomX Therapeutics, Inc. (CTMX) worth $5.18 M, representing 0.01% of the portfolio. First purchased in 2019-Q4, this medium-term investment has been held for 17 quarters.
Based on 13F filings, Paul Tudor Jones has maintained a strategic position in CTMX, demonstrating sustained confidence in this investment. Largest addition occurred in Q2 2026, adding 1.38 M shares. Largest reduction occurred in Q1 2023, reducing 118,267 shares.
Analysis based on 13F filings available since 2013 Q2
Paul Tudor Jones's CytomX Therapeutics (CTMX) Holding Value Over Time
Track share changes against reported price movement
Quarterly CytomX Therapeutics (CTMX) Trades by Paul Tudor Jones
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q2 2026 | +1.38 M | New Buy | 1.38 M | $3.75 |
| Q2 2024 | -43,865 | Sold Out | 0 | $0.00 |
| Q1 2024 | -865 | Reduce 1.93% | 43,865 | $2.18 |
| Q1 2023 | -118,267 | Reduce 72.56% | 44,730 | $0.00 |
| Q1 2022 | +162,997 | New Buy | 162,997 | $2.67 |
| Q1 2021 | -51,873 | Sold Out | 0 | $0.00 |
| Q4 2020 | -47,068 | Reduce 47.57% | 51,873 | $6.55 |
| Q3 2020 | +74,370 | Add 302.67% | 98,941 | $6.65 |
| Q2 2020 | -18,720 | Reduce 43.24% | 24,571 | $8.34 |
| Q1 2020 | -35,488 | Reduce 45.05% | 43,291 | $7.67 |
| Q4 2019 | +78,779 | New Buy | 78,779 | $8.31 |
Paul Tudor Jones's CytomX Therapeutics Investment FAQs
Paul Tudor Jones first purchased CytomX Therapeutics, Inc. (CTMX) in Q4 2019, acquiring 78,779 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Paul Tudor Jones has held CytomX Therapeutics, Inc. (CTMX) for 17 quarters since Q4 2019.
Paul Tudor Jones's largest addition to CytomX Therapeutics, Inc. (CTMX) was in Q2 2026, adding 1,380,687 shares worth $5.18 M.
According to the latest 13F filing for Q2 2026, Paul Tudor Jones's firm, Tudor Investment Corp Et Al, owns 1,380,687 shares of CytomX Therapeutics, Inc. (CTMX), valued at approximately $5.18 M.
As of the Q2 2026 filing, CytomX Therapeutics, Inc. (CTMX) represents approximately 0.01% of Paul Tudor Jones's publicly disclosed stock portfolio, making it one of their key holdings.
Paul Tudor Jones's peak holding in CytomX Therapeutics, Inc. (CTMX) was 1,380,687 shares, as reported at the end of Q2 2026.